Bausch Health announces CABTREO receives positive reimbursement recommendations

Bausch Health (BHC) announced that CABTREO gel 1.2% w/w, 0.15% w/w and 3.1% w/w, a new triple-combination topical prescription treatment for acne vulgaris in patients 12 years of age and older,1 has received positive reimbursement recommendations from Canada’s Drug Agency and Quebec’s Institut national d’excellence en sante et en services sociaux. The recommendations are an important element in the process to achieve reimbursement of a new medication by Canada public drug plans operated by the provinces, territories and federal government. Bausch Health, Canada will now work with the pan-Canadian Pharmaceutical Alliance to agree on the particulars regarding the reimbursement of CABTREO by Canada’s public drug plans. CABTREO is the first and only triple-combination topical treatment for acne approved by Health Canada with three mechanisms of action – an antibiotic, a retinoid and an antibacterial agent – to provide a safe and effective treatment. CABTREO is a topical gel that is administered once daily to affected areas of the skin. Its active ingredients are the antibiotic clindamycin phosphate, the topical retinoid adapalene, and the oxidizing agent benzoyl peroxide which has a broad-spectrum bactericidal activity. The prescription therapy is available now through pharmacies across Canada.